Cancer News and Research

Latest Cancer News and Research

Hydro-stomach CT imaging is not a reliable tool for EGC detection: Study

Traditionally, both air and tap water have been used as oral contrast agents to achieve adequate gastric distension for preoperative computed tomography imaging in patients with early gastric cancer.

16 Mar 2011

Self-sample HPV test can help increase cervical screening uptake among women

Home tests for the human papillomavirus could help increase the take-up of cervical screening among women who do not respond to screening invitations, new research shows today.

16 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

Vitamin D deficiency is a well reported complication in chronic cholestatic liver disease such as primary biliary cirrhosis. While the prevalence and treatment of this deficiency has been addressed in many articles over the last decades, little is known of the vitamin D status in alcoholic liver cirrhosis.

16 Mar 2011

NMS announces license agreement with Novartis

Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a license agreement with Novartis.

16 Mar 2011

iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection.

16 Mar 2011

Human growth, height, size: Reasons to be small

Almost everybody these days thinks that it is best to be tall, meaning much taller than the average traditional height of Asian populations, and even taller than the current average height of populations in high-income countries. It is also often believed – though people might be shy to admit this – that tall people are intrinsically superior to short people. The expressions 'look up to' and 'look down on' are significant.

15 Mar 2011

Heavy drinking related to pancreatic cancer: Study

According to the latest research, heavy drinkers have an increased risk of dying from pancreatic cancer. The study has shown that non-smokers who have three or more drinks of hard liquor a day face a 36 percent higher risk of dying from pancreatic cancer, compared with non-drinkers. Smoking is a definite risk for pancreatic cancer. The report is published in the March 14 issue of the Archives of Internal Medicine.

15 Mar 2011

Heavy smoking dropped drastically over last four decades: Study

A new study has shown that the rate of “pack-a-day” or more smokers in the United States has fallen sharply since 1965, particularly in California. There is evidence from earlier literature that a smaller percentage of Americans smoke now than in previous decades. This new study was published online in the Journal of the American Medical Association. It shows that high-intensity smoking is also less common.

15 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Newer, more expensive treatments for prostate cancer adopted rapidly

With 180,000 men diagnosed with prostate cancer each year, it is one of the most common types of cancer in the country. For this reason, it has been cited as a good marker for health care spending in general, reflective of the greater trends across the United States.

15 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Research links frequent prescribing to opioid-related deaths

Some physicians are prescribing opioids such as OxyContin 55 times as often as others, according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). The study found most opioid-related deaths occur among patients treated by physicians who frequently prescribe opioids, suggesting doctors who prescribe a lot of opioids may not be doing so safely.

15 Mar 2011

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

XTIO2 INC. (XTI) presented the 83rd Academy® Award-nominees with the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM, consisting of XTI 360™ Nanocoating and XTI™ Nano-Facemask. It is the world's most effective preventive measure and the best defense against germs transmitted via air and contact surfaces.

15 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Medidata fourth quarter net revenue is $47.4 million for 2010

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the fourth quarter 2010 and full year ended December 31, 2010, as well as provided financial guidance for the first quarter and full year 2011.

15 Mar 2011

Researchers discover new key component in lung cancer spread

Researchers discovered a new, key component in the spread of lung cancer as well as a likely way to block it with drugs now in clinical trial. The study was published today (Monday, March 14) in the Journal of Clinical Investigation.

15 Mar 2011